

Taia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4260459/publications.pdf>

Version: 2024-02-01

41
papers

7,084
citations

279798

23
h-index

395702

33
g-index

57
all docs

57
docs citations

57
times ranked

16446
citing authors

#	ARTICLE	IF	CITATIONS
1	Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. <i>Cell</i> , 2020, 181, 1036-1045.e9.	28.9	3,572
2	Type I and type II Fc receptors regulate innate and adaptive immunity. <i>Nature Immunology</i> , 2014, 15, 707-716.	14.5	425
3	Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. <i>Science Immunology</i> , 2020, 5, .	11.9	404
4	IgG antibodies to dengue enhanced for Fc γ RIIIA binding determine disease severity. <i>Science</i> , 2017, 355, 395-398.	12.6	286
5	New-onset IgG autoantibodies in hospitalized patients with COVID-19. <i>Nature Communications</i> , 2021, 12, 5417.	12.8	286
6	Proinflammatory IgG Fc structures in patients with severe COVID-19. <i>Nature Immunology</i> , 2021, 22, 67-73.	14.5	239
7	Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 28, 516-525.e5.	11.0	219
8	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	13.7	180
9	Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. <i>Cell</i> , 2015, 162, 160-169.	28.9	171
10	Signaling by Antibodies: Recent Progress. <i>Annual Review of Immunology</i> , 2017, 35, 285-311.	21.8	167
11	Functional diversification of IgGs through Fc glycosylation. <i>Journal of Clinical Investigation</i> , 2019, 129, 3492-3498.	8.2	115
12	Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. <i>Nature Communications</i> , 2021, 12, 1967.	12.8	107
13	Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. <i>Nature Biotechnology</i> , 2021, 39, 928-935.	17.5	106
14	The Role and Function of Fc γ Receptors on Myeloid Cells. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	96
15	Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. <i>Science Translational Medicine</i> , 2022, 14, eabn7842.	12.4	92
16	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	13.7	75
17	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. <i>Science Translational Medicine</i> , 2022, 14, eabm7853.	12.4	71
18	Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. <i>MSphere</i> , 2020, 5, .	2.9	62

#	ARTICLE	IF	CITATIONS
19	FcRn, but not FcÎ³Rs, drives maternal-fetal transplacental transport of human IgG antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12943-12951.	7.1	55
20	Maternal Anti-Dengue IgG Fucosylation Predicts Susceptibility to Dengue Disease in Infants. Cell Reports, 2020, 31, 107642.	6.4	44
21	Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10172-10177.	7.1	42
22	IgG Fc Glycosylation in Human Immunity. Current Topics in Microbiology and Immunology, 2019, 423, 63-75.	1.1	38
23	Immunological responses to influenza vaccination: lessons for improving vaccine efficacy. Current Opinion in Immunology, 2018, 53, 124-129.	5.5	24
24	An aberrant inflammatory response in severe COVID-19. Cell Host and Microbe, 2021, 29, 1043-1047.	11.0	24
25	Immune Complexes: Not Just an Innocent Bystander in Chronic Viral Infection. Immunity, 2015, 42, 213-215.	14.3	20
26	Immunity after SARS-CoV-2 infections. Nature Immunology, 2021, 22, 539-540.	14.5	20
27	Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to postâ€œCOVID-19 syndrome. JCI Insight, 2022, 7, .	5.0	18
28	TNF-Î±+ CD4+ TÂĈells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell Reports Medicine, 2022, 3, 100640.	6.5	15
29	Heterogeneity in IgGâ€™CD16 signaling in infectious disease outcomes*. Immunological Reviews, 2022, 309, 64-74.	6.0	9
30	The Role and Function of FcÎ³ Receptors on Myeloid Cells. , 2017, , 405-427.		8
31	Differential Peripheral Blood Glycoprotein Profiles in Symptomatic and Asymptomatic COVID-19. Viruses, 2022, 14, 553.	3.3	7
32	Immunity by Design. Cell Host and Microbe, 2018, 23, 430-431.	11.0	3
33	Harnessing IgG Fc glycosylation for clinical benefit. Current Opinion in Immunology, 2022, 77, 102231.	5.5	3
34	Immunoglobulin E sialylation regulates allergic responses. Immunology and Cell Biology, 2020, 98, 617-619.	2.3	2
35	lluminating the Fc dependence of SARS-CoV-2 neutralization. Immunity, 2021, 54, 1912-1914.	14.3	1
36	Original antigenic sin strikes again?. Science Translational Medicine, 2015, 7, .	12.4	0

#	ARTICLE	IF	CITATIONS
37	Two-pronged approach to prevent pneumonia. Science Translational Medicine, 2015, 7, .	12.4	0
38	Passenger mutations: Backseat drivers in failed translation. Science Translational Medicine, 2015, 7, .	12.4	0
39	Polypharmacy repercussions. Science Translational Medicine, 2015, 7, .	12.4	0
40	Influenza antibody archaeology. Science Translational Medicine, 2016, 8, .	12.4	0
41	A puzzling path from infection to Guillain-Barré syndrome. Science Translational Medicine, 2016, 8, .	12.4	0